Analyst Reco. Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
28 ^USD	-0.39%		-0.57%	-0.32%

Apr. 17	Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	MT
Apr. 17	Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	Apr. 09	MT
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating	Feb. 20	MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $50 From $56, Keeps Buy Rating	Feb. 20	MT
Morgan Stanley Cuts Price Target on Royalty Pharma to $46 From $57, Keeps Overweight Rating	Dec. 12	MT
ANALYST RECOMMENDATIONS : Adobe, Amgen, Blackrock, IBM, Ulta Beauty...	Dec. 12
Morgan Stanley Adjusts Price Target on Royalty Pharma to $57 From $54, Maintains Overweight Rating	Nov. 09	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $54 From $53, Maintains Overweight Rating	23-10-11	MT
UBS Adjusts Royalty Pharma Price Target to $41 From $44, Maintains Buy Rating	23-08-09	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $53 From $52, Maintains Overweight Rating	23-08-09	MT
UBS Adjusts Royalty Pharma Price Target to $44 From $48, Maintains Buy Rating	23-07-24	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $52 From $50, Maintains Overweight Rating	23-05-10	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $50 From $48, Maintains Overweight Rating	23-04-10	MT
Fitch Affirms Royalty Pharma plc at 'BBB-'; Outlook Stable	23-04-04	AQ
Bank of England lifts rates by 25 basis points	23-03-23	AN
UBS Adjusts Royalty Pharma's Price Target to $48 From $51, Maintains Buy Rating	23-02-16	MT
Morgan Stanley Cuts Price Target on Royalty Pharma to $51 From $54, Maintains Overweight Rating	22-12-06	MT
UBS Adjusts Royalty Pharma Price Target to $51 From $50, Maintains Buy Rating	22-11-09	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $54 From $51, Maintains Overweight Rating	22-11-09	MT
JPMorgan Chase Adjusts Royalty Pharma's Price Target to $52 From $50, Keeps Overweight Rating	22-10-18	MT
Morgan Stanley Increases Royalty Pharma's Price Target to $51 From $48, Maintains Overweight Rating	22-08-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Analyst Reco.

Filters